Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction

European Heart Journal

Danish registry review of 46,301 pts on dual antiplatelet treatment after MI found only 35% at higher risk of upper gastrointestinal (UGI) bleeding received treatment with PPI based on the guideline criteria. Use of a PPI was associated with a lower 1-year risk of UGI bleedings.

Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation

Heart

Review summarises currently available data and suggests a more individualised antithrombotic treatment strategy after transcatheter aortic valve implantation based on risk factors for cardiovascular events and bleeding.

Emicizumab (Hemlibra) approved in EU for prevention of bleeding episodes in people with severe haemophilia A without factor VIII inhibitors

PharmaTimes

The decision follows results of the Phase III HAVEN 3 study. Emicizumab is already licensed for routine prophylaxis of bleeding episodes in patients with haemophilia A with factor VIII inhibitors.

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:

http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services